Circulating tumour DNA (ctDNA) is transforming how we diagnose and treat complex cancers, particularly when clinical pathways ...

Myriad will launch Precise MRD with select community-based clinicians in March 2026 in breast, followed by colorectal and renal cancers later this year. The company may expand into additional cancer ...

A simple blood test measuring circulating tumor DNA (ctDNA) could help doctors predict how well treatment will work for some patients with advanced breast cancer.

Circular tumor DNA (ctDNA) positivity is associated with poorer survival and higher recurrence rates among patients with non–small cell lung cancer (NSCLC), but early detection may allow for timely ...

Exclusive: DNA test means patients could be offered most effective treatment first, boosting their chances of beating the disease ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

Circulating tumor DNA (ctDNA) is a blood test that looks for tiny pieces of cancer DNA released by dying cells, allowing doctors to detect cancer using a simple blood sample, Dr. Nicholas Hornstein ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...